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Abstract
Most lysosomal diseases (LD) are inherited as autosomal recessive traits, but two important conditions have
X-linked inheritance: Fabry disease and Mucopolysaccharidosis II (MPS II). These two diseases show a very different
pattern regarding expression on heterozygotes, which does not seem to be explained by the X-inactivation
mechanism only. While MPS II heterozygotes are asymptomatic in most instances, in Fabry disease most of female
carriers show some disease manifestation, which is sometimes severe. It is known that there is a major difference
among X-linked diseases depending on the cell autonomy of the gene product involved and, therefore, on the
occurrence of cross-correction. Since lysosomal enzymes are usually secreted and uptaken by neighbor cells, the
different findings between MPS II and Fabry disease heterozygotes can also be due to different efficiency of cross-
correction (higher in MPS II and lower in Fabry disease). In this paper, we review these two X-linked LD in order
to discuss the mechanisms that could explain the different rates of penetrance and expressivity observed in the
heterozygotes; this could be helpful to better understand the expression of X-linked traits.
Introduction
The lysosomal disorders (LD) are a heterogeneous group
of approximately 50 disorders [1,2] with prevalence
around 1:5,000 to 1:7,000 in live births [3,4]. Among
other mechanisms involved in the degradation of macro-
molecules in lysosomes, the disease may be due to the
deficiency of a specific hydrolase, a defect on the post-
translational processing of the enzyme, or a transport
defect across the lysosomal membrane [2,5]. The defi-
ciency of a single enzyme or protein causes the blockage
of an entire pathway making the substrate inaccessible
to further hydrolysis by other lysosomal enzymes. It is
important to stress that the gene products involved in
the LD usually are not cell autonomous, as they could
be secreted and uptaken on cells which do not produce
them. Furthermore, in most LD more than one com-
pound is accumulated, as in Mucopolysaccharidosis II
(MPS II or Hunter syndrome), in which the main sto-
rage materials are dermatan sulphate and heparan sul-
phate; however, other substrates like ganglioside GM2
and GM3 and subunit c of mitochondrial ATP synthase
are also accumulated in the brain [6]. The new concepts
in cell biology led to the proposal of a new classification
of LSD by Platt and Walkley [2] (Table 1).
Among the over 300 human X-linked diseases
described so far, only three are LD: Fabry disease (MIM
301500), MPSII II (MIM 30900), and Danon disease
(MIM 300257). This review will focus on the clinical
heterogeneity found among heterozygotes of the two
most frequent conditions: Fabry disease and MPS II.
Fabry disease
Fabry disease is a rare X-linked lysosomal inborn error
of glycosphingolipid catabolism which results from the
deficient activity of lysosmal hidrolase a galactosidase
A( a-GAL; EC 3.2.1.22). The estimated incidence of
this rare disease is 1:40,000-117,000 live male births
[4,7,8]. This figure, however, may be underestimated,
as screening performed in newborn males in a North-
western Italian region showed an incidence of 1 in
~4,000 males [9]. The a-galactosidase gene (GLA
300644) is located in Xq22.1 and spans 12 kb of DNA
comprising 7 exons [8]. More than 400 mutations in
the GLA gene have been described in Fabry patients,
most of them private [10-12]. The enzyme deficiency
leads to a progressive accumulation of globotriaosyl-
ceramide (Gb3) and deacylated globotriaosylsphingo-
sine (lyso-Gb3).
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the vascular endothelium, renal glomeruli and tubules,
dorsal root ganglia, cardiac myocytes, conduction tissue
and valves, cornea and skin. Signs and symptoms
include: angiokeratoma, progressive renal impairment,
proteinuria, acropharestesia of hands and feet, cardiac
hypertrophy and conduction abnormalities, ischemic
events, corneal dystrophy, hypohidrosis and impaired
temperature regulation [8,11-13]. A mother and her son
with Fabry disease are shown in Figure 1.
The prevalence of females carrying the Fabry mutation
was estimated as 1:339,000 in the UK [14]. Heterozygote
females were usually described as asymptomatic or as
exhibiting intermittent and mild symptoms of the dis-
ease [7,8]. The most common signs and symptoms in
Fabry disease are shown in Table S1, Additional file 1
[8,14-19]. Deegan et al.[ 1 6 ]s h o w e dt h a t7 0 %o ft h e
heterozygote females may display signs and/or symp-
toms. The disease in females can be as severe as in male
patients [7,20,21]; however, a slow rate of progression
and a high phenotypic variability is more common
[14,22]. Life expectancy is reduced in about 20 years in
heterozygous females [23].
The measurement of the a-GAL activity does not
always allow the identification of the heterozygotes
[8,23], and it is believed that there is no correlation
Table 1 Classification of LSDs (adapted from Platt and Walkley, 2004 [2])
Molecular defect Enzyme deficiency Disease example OMIM
number
Primary lysosomal hydrolase defect a-Galactosidase A
Iduronate-sulfatase
Fabry disease
MPS II
301500
309900
Post-translational processing defect of
lysosomal enzymes
Multiple sulphatase deficiency
(17 sulphatases)
Multiple sulphatase
deficiency
272200
Trafficking defect for lysosomal enzymes N-acetylglucosamine-1-phosphotransferase Mucolipidosis type II 252500
Defect in lysosomal enzyme protection b-Galactosidase and Neuraminidase deficiency Galactosialidosis 256540
Defect insoluble non-enzymatic lysosomal
proteins
Hexosaminidase activator deficiency GM2 type AB
(Tay-Sachs disease variant AB)
272750
Transmembrane (non-enzyme) protein
defect
Lysosomal-associated membrane protein 2 Danon disease 300257
Unclassified Intracellular accumulation of autofluorescent of
lipopigments storage material
Neuronal ceroid
lipofuscinoses (CLN4)
204300
Figure 1 Male patient with Fabry disease (left, child) and a heterozygote for Fabry disease (right, mother). The male patient is 21 years
old and presents pain in hands and achroparestesias, temperature intolerance, hypohidrosis, and proteinuria. He presents a 30delG in the a-GAL
gene. The mother is 62 years old and has diabetes mellitus, cardiopathy and proteinuria. She is a carrier of 30delG in the a-GAL gene. Image use
authorized by patients.
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type and the severity of the clinical picture presented by
heterozygotes [2]. However, some authors stated that
females with classic Fabry disease usually have lower a-
GAL activity and increased urinary Gb3 levels [24]. On
women suspected of presenting Fabry disease due to
symptomatology or findings on a tissue biopsy but with
a negative family history, DNA analysis is often required
for the definitive diagnosis [15,25]. On the other hand,
Wilcox et al. [18] showed that leukocyte a-GAL activity
can point to diagnosis in 88% of females; this suggests
that used in conjunction with urinary Gb3 measurement
[26] this test may be an efficient way to screen females
at high risk to be carriers.
Mucopolysaccharidosis type II
The incidence of MPS II is estimated between
1:110,000 and 132,500 live births [27,28]. MPS II is an
X-linked recessive inborn error of metabolism that
results from the deficiency of lysosomal iduronate-2-
sulfatase (IDS; EC 3.1.6.13). The impaired IDS function
leads to the storage of glycosaminoglicans (GAGs) in
many organs and tissues. The partially degraded GAGs
are heparan sulfate and dermatan sulfate, which are
present in increased concentrations in the urine of
patients. The IDS gene was mapped to Xq28 and con-
tains 9 exons that spread over 24 kb [29,30]. More
than 300 mutations have been described [10]. And
there is also a pseudogene located 20 kb from the
a c t i v eg e n e[ 3 1 ] .
MPS II is also a multisystemic disorder, which includes
the following main manifestations: coarse facies, short
stature, hepatosplenomegaly, dysostosis multiplex, joint
contractures, obstructive airway disease, deafness, hydro-
cephaly, recurrent sinopulmonary infections, valve dis-
ease and, in some patients, mental impairment [32]. The
disease is classified as mild or severe according to the
absence or presence of mental retardation [33,34]. MPS
II is chronic, progressive, and, in its severe form, death
can occur as early as at the age of 15. Cardiac and pul-
monary diseases are the most common cause of death
[32]. A heterozygote mother and her child affected with
MPS II are shown in Figure 2.
In MPS II, the clinical disease in females is very rare, and
most of the cases reported in the literature have the severe
phenotype [35-43] (Table S2, Additional file 2). At least
ten female cases have already been described [43].
In most cases, the identification of heterozygote
females with MPS II by the measurement of the IDS
activity is not reliable [32,44,45]. It is suggested that the
lower the value of IDS, the higher the probability that
these women will be a heterozygote [32]. Unfortunately,
GAGs measurement in the urine is not helpful to iden-
tify carriers either [46]. Usually, the only way to reach
the definitive diagnosis is through genetic analysis [47].
X-Linked Inheritance
X-linked inheritance was first described by Morgan
[48,49], and colorblindness was one of the first diseases
to be recognized as having this pattern of inheritance
Figure 2 Male patient with MPS II (left, child) and a heterozygote for MPS II (left, mother). The patient is 10 years old and presents severe
mental handicap, coarse face, hepatosplenomeagly, dysostosis multiplex, joint contractures, obstructive airway disease, mitral regurgitation,
deafness, and hydrocephaly. He presents a total deletion of the IDS gene. The mother is a MPS II carrier and is asymptomatic. Image use
authorized by patient.
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cal transmission in which heterozygote females transmit
the allele down to her sons and daughters; daughters of
affected males are always heterozygotes; sons of affected
males are always normal. Traditionally, these diseases
are described as dominant if they are expressed both in
heterozygotes and hemizygotes, or as recessive if they
are expressed predominantly or almost exclusively in
males. A subgroup of X-linked dominant disorders
includes those characterized by male lethality or reduced
male-viability (X-linked dominant male-lethal disorders)
while semidominant X-linked diseases would occur
when the heterozygotes present a phenotype intermedi-
ate to the phenotype of affected hemyzygotes and nor-
mal homozygotes [50].
It is true that the vast majority of mutations in X-
linked genes will lead to diseases only in males [51].
However, many of the X-linked diseases show different
rates of penetrance and expressivity in both genders.
The following situations can be observed: 1) for some
conditions, such as Fabry disease, heterozygotes are
usually affected but tend to have a milder and more
variable phenotype than hemizygotes (e.g., semidomi-
nant inheritance); 2) for other diseases, as MPS II, pene-
trance in heterozygotes is very low and, consequently,
very few heterozygotes are affected (e.g., recessive
inheritance); 3) on the other hand, as in Vitamin D
resistant rickets, penetrance and severity are high in
both genders (e.g., dominant inheritance); 4) finally, as
in Rett syndrome, penetrance is high in both genders,
but males usually die very early (intrauterus), and only
females are usually affected at birth (e.g., lethal domi-
nant inheritance) [21,48,52].
Classification of X-linked disorders
According to Dobyns et al. [48], the traditional classifica-
tion of X-linked diseases in dominant or recessive should
not be used for humans. The authors made this statement
because this classification was originally based on the Dro-
sophila model, and some concepts cannot be applied to
humans, since there are differences in sex determination
and dosage compensation for genes on the X chromosome
between the two species (Table 2). The mechanism that is
responsible for dosage compensation in Drosophila is
based on the X transcription speed, which is higher in
males, and not in X-inactivation. Therefore, a Drosophila
female that is heterozygous for a null mutation in an X-
linked gene will not present cell mosaicism as it would be
expected in female human cells. In other words, as the
concept of dominance and recessivity depends on the
expression on the two alleles inside the cell, it would not
be applied to X-linked diseases, as in most of these condi-
tions only one allele is expressed in the cell due to the X-
inactivation mechanism [53].
Based on a literature review, Dobyns et al.[ 4 8 ]c l a s -
sified 32 X-linked diseases according to penetrance
(high, intermediate, and low) and severity index (pro-
portion of all symptomatic individuals with a pheno-
type classified as severe among all symptomatic
carriers) both for males and females. Fabry disease was
classified as presenting high penetrance (100%) and
high severity index (84%) for males; for females, how-
ever, the penetrance was high (70%) but the severity
index was not (4%). For MPS II, males were also found
to present high penetrance (100%) and severity index
(81%); females, however, presented both low pene-
trance and low severity index rate. This low severity
index rate for MPS II females [48] could be contested,
as the majority of the patients described presented the
severe form of the disease (Table S2,A d d i t i o n a lf i l e
2). Due to the clinical heterogeneity found, these
authors suggested that X-linked disorders should be
analysed taking into account biological mechanisms
other than X-inactivation, such as the cell-autonomy
of the gene product and its early toxicity to the cell
(Table 3). In the lethal X-linked dominant diseases, the
gene product would be detrimental to the cell at very
early stages and, as a consequence, the viability of the
affected males would be reduced; expressivity would be
variable in heterozygotes, e.g., a combined effect of
both the X-inativaction pattern and positive and nega-
tive selection mechanisms [50].
Twinning and X-Linked Diseases
Discordant phenotypes in monozygous twin females
(MZF), who were heterozygous for X-linked disorders,
have already been reported for many diseases, including
Duchenne Muscular Dystrophy (DMD), G6PD defi-
ciency, Haemophilia B, Fragile-X syndrome, Green color
deficiency, MPS II and Fabry disease [39,54-60]. Clinical
expression of the X-linkedd i s e a s e si no n eo ft h eM Z F
s e e m st ob ep r o p o r t i o n a l l ym o r ef r e q u e n tt h a nt h e
expression in heterozygote females. Also, it seems that
concordant expression between MZF heterozygotes has
never been reported [60].
Table 2 Comparison between Drosophila and humans
regarding the compensation-dose mechanism (based on
Dobyns et al., 2004 [48])
Characteristics Drosophila Human
Female 6A+XX 46, XX
Male 6A+XY 46, XY
Fertile 6A+XX and 6A+XY 46, XX and XY
Infertile 6A+XO 45, X
Dosage compensation in
X chromosome
Transcribing rate of the
X chromosome
X-inactivation
X- inactivation No Yes
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type were described in the literature. Only one MZF
pair was confirmed regarding monozigosity. At the age
of 26 years, the affected MZF presented severe signs and
symptoms: renal proteinuria, angiokeratotic lesions in
the pelvic region and thighs, verticillate cornea, and
acroparesthesia in all four limbs. Both MZF were het-
erozygous for the G10182A mutation (exon 5). The phe-
notype was attributed to the skewed X-inactivation
favoring the GLA allele mutant in the affected MZF,
showing an opposite direction in the normal MZF
[54-56]. For female MZF MPS II twins, only one case
has been described in the literature, and the affected
twin had a normal karyotype and skewed X-inactivation
also favoring the IDS mutant allele [39].
Tiberio [60] reviewed some characteristics common to
the X-linked diseases in MZF as follows: 1) karyotypes
are normal; 2) one twin is severely affected and the
other is spared; 3) intermediate phenotypes have not
been described; 4) the X-inactivation pattern is opposite
to skewing (abnormal allele inactivated in most cells of
the normal twin, and the normal allele inactivated in
most cells of the affected twin), and 5) the disease maps
into regions Xq27-28, Xp21, Xq22 and Xp22. Due to
these observations three hypotheses came up to explain
the discordant phenotype in these cases: 1) casual aggre-
gation of cells carrying the same inactive chromosome
that predisposes twining [61]; 2) a “sampling effect”
through early symmetric or asymmetric splitting of the
inner cell mass occurring after the X-inactivation
[61,62], and 3) early mitotic crossing over, segregation
of one crossed and one uncrossed chromatid in the
daughter’s cells, and obligate inactivation of the
uncrossed chromatid [63]. Unfortunately, it seems that
none of these hypotheses can completely explain the
MFZ discordant for X-linked diseases [60].
The X-inactivation occurs very early in embryonic life
in the late blastocyst stage of embryogenesis [41,63], and
one possible explanation of the variable expression of an
X-linked abnormality in MZF lies on the fact that
X-inactivation precedes the twinning event
[56,57,61,64-66]. It was also observed that in MZF who
are dichorionic, twinning occurs prior or around the
onset of X-inactivation and, in monochorionic twins,
twinning occurs later [67]. So it might be expected that
discordant phenotype should be more frequent in twins
dichorionic; however, anedoctal cases of discordant X-
linked diseases in dichorionic MZF have already been
reported [39,58]. A new explanation proposed by Mon-
teiro et al. [65] is that monochorionic MZF is, in fact, a
heterogeneous group that differs in the timing of the
twinning event after the onset of X-inactivation [59].
There are many other possible explanations for discor-
dant phenotypes between monozygotic twins: environ-
mental causes, several embryologic mechanisms,
vascular abnormalities, defect of midline structures and
postzygotic changes in the genetic material, including
somatic mutations [62].
X-Inactivation, Fabry Disease and MPS II
The main question to be answered is if skewed X-inacti-
vation is the main mechanism responsible for the differ-
ent rates of penetrance and expressivity presented by
heterozygotes for Fabry and MPS II diseases (Table 3).
X-inactivation process
The X-inactivation was first described by Lyon [68,69],
who suggested that the X-inactivation was based on the
pattern of patches in heterozygote female mice. This
author proposed some general rules for X-inactivation:
1) normal females have just one active X chromosome;
2) X-inactivation occurs early in development; 3) the
Table 3 Relation between genic product properties, cellular selection, X-inactivation and phenotype of heterozygotes
for X-linked diseases: the example of Fabry disease and MPS II (based on Dobyns et al., 2004 [48] and Dobyns, 2006
[53])
Type of gene product Positive cellular selection (gene
product causing early cell death)
Clinical Phenotype in
Heterozygotes
Probably X-inactivation
Pattern
Disease
Cell-autonomous No Normal Random or skewed favorable to
the normal allele
Fabry
disease
3
No Abnormal Random or skewed unfavorable
to the normal allele
4
Fabry
disease
3
Non-cell-autonomous
1 or
functionally non-autonomous
2
No Normal Random or skewed favorable to
the normal allele
MPS II
No Abnormal Skewed favorable to the
abnormal allele
MPS II
1Non-autonomous gene products would include primarily secreted proteins;
2Functionally non-autonomous would include proteins expressed in non-clonal,
multinucleated cells and small molecules that pass freely between cells;
3Athough the genic product of Fabry disease is non-cell autonomous, the hypothesis is
that cross-correction capacity in this disease is low and, as a result, it is being classified in this table as cell-autonomous.
4The phenotype can be modulated by
the presence of a randomic X-inactivation, e.g., the phenotype is abnormal, and/or by an unfavourable skewed to the normal allele; then, a more severe
phentoype is expected.
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random, and d) X-inactivation is irreversible in somatic
cells and through all its descendants. Because females
have two X chromosomes and males only one, the X-
inactivation provides a mechanism called “compensation
dose”. As a result, females are mosaic [21].
The X-inactivation process is dependent on many fac-
tors and is tissue specific [52]. It is initiated on the
X-inactivation center (Xic) located at Xq13.2 [70]. The
X-inactivation specific transcript (Xist; MIM 314670)
gene is responsible for the process of cis inactivation
[71], and it is transcribed only in the inactive X chromo-
s o m e .I nX i c ,i ti sa l s ot r a n s c r i b e d ,i nt h ea n t i s e n s e
orientation, the X-inactive specific transcript-antisense
(Tsix; MIM 300181) that has the function of regulating
the early expression and the choice of which X chromo-
some will be inactivated [72]. As the X-inactivation pat-
tern is established, all descendents cells will have the
same pattern. X-inactivation in somatic cells is very
stable [73], permanent and irreversible, except in oogen-
esis and in spermatogenesis [74]. The main steps of
inactivation are: counting, choice and initiation [75].
Actually, the first step is to maintain one of the active
X chromosomes [21], and this is attributed to the exis-
tence of an autosomal limited factor [73]. Many epige-
netics modifications are necessary to guarantee the
maintenance and the herdability of the X-inactivation
[76]. However, not all genes present in the X chromo-
some are inactive, and it is estimated that about 25% of
the genes [77] escape from the inactivation, most of
them located in the X chromosome short arm.
Lyonization follows the Gaussian distribution in the
female population, and it is expected that females would
be 50:50 for genes that underwent X-inactivation, but
ratios 60:40 or 70:30 are the most common [78], and
even 80:20 or 90:10 can be considered normal [51,67].
However, it was shown that at least 5-10% of normal
females present extreme skewing of X-inactivation [79],
while some studies showed a range between 4% and
33% [80]. Extreme skewed X- inactivation is defined as
affecting more than 90% of one allele [81] and may be a
consequence of the following: 1) biases in the choice of
which X chromosome to inactivate; 2) X chromosome
mutations or rearrangements which affect the viability
of cells with one or the other active X, or 3) stochastic
factors [73,78]. Highly skewed X-inactivation, defined as
more than 80:20, could be pathogenic [82].
Studies in peripheral blood cells show that skewing of
inactivation increases with age, but the practical signifi-
cance of this finding is uncertain. However, it is possible
that skewing in an advanced age is correlated with the
presence of a pathogenic allele in the X chromosome
[78]. The age-skewing process can be caused by stochas-
tic clonal loss of hematopoietic cells [83] or the
competitive advantage for hematopoietic stem cells with
a specific genotype of X-linked genes [84].
Skewed X-inactivation and diseases
Traditionally, the main mechanisms that are said to
influence the expression of the X-linked disorders are:
skewed inactivation [43,69,85,86], clonal expansion, and
somatic mosaicism [87]. Therefore, heterozygotes for X-
linked diseases could be symptomatic if: 1) the mutation
confers a proliferative advantage to the mutant cells, OR
2) there is skewed X-inactivation due to any reason (X/
autosomal translocation, mutation in the XIST gene,
etc), and the mutant is in the active X chromosome
[36,43,87]. However, there are other explanations for the
heterozygotes for an X-linked disease presenting with
signs and symptoms, such as the occurrence of hemizy-
gozity for the mutant allele (e.g., the patient is a carrier
of the mutation but full X monosomy is present); the
occurrence of uniparental disomy for the mutant X
chromosome, and the absence (or deficiency) of cross-
correction [39]. Structural rearrangements involving the
X chromosome, as X/autosomal translocations and dele-
tions, could disrupt the normal allele and may cause
loss of heterozygozity or contiguous gene syndromes.
Several diseases, such as DMD, had their genes mapped
to the X chromosome after patients with rearrange-
ments involving the same X chromosome region were
identified. In the case of MPS II, patients presenting
deletions involving not only the IDS gene but also the
FMR1 (involved in the X-fragile syndrome) have been
described [88].
As previously mentioned, skewed X-inactivation has
been shown to be responsible for clinical manifestations in
female carriers of X-linked diseases, such as DMD [57].
Skewed X-inactivation also seems to be involved in other
situations such as recurrent pregnancy loss [89,90] and
breast cancer [91]. Deviation from the random X-inactiva-
tion can be primary or secondary. Primary as a result of
the deviation of X-inactivation itself, e.g., a mutation in
XIST gene, or secondary if the non-random X-inactivation
has a consequence like cell selection [22,92].
It is possible to identify four X-inactivation patterns in
heterozygotes for X-linked diseases as follows: 1) ran-
dom inactivation is usually associated with a normal
phenotype; 2) random inactivation leads to manifesta-
tions in a continuum spectrum, and a normal phenotype
requires skewing, favoring the normal allele in the
expressing tissue; 3) always extreme skewing, as mutant
cells die or fail to develop, or migrate to destination; 4)
gradual skewing because of cell selection due to a prolif-
erative advantage of wild type (or mutant) cells expres-
sing tissue [21].
Unbalanced X-inactivation can occur as a stochastic
variation or due to genetic factors influencing the
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mechanism [22]. The first two are rare and occur inde-
pendent of the kind of mutation in the gene of the dis-
ease [22,67].
Fabry Disease: Explanations for the Female
Phenotype
Symptomatic heterozygous females for Fabry disease can
be as frequent as 60-70% [22,93]. Sometimes, symptoms
are as severe as in males [7,93]. It has been suggested
that X inactivation studies could be helpful in predicting
the female phenotype in Fabry disease [11,22]. For some
authors [8,15,23] skewed X-inactivation plays an essen-
tial role in the phenotype expression in heterozygotes of
Fabry disease. Dobrovolny et al. [11] showed that some
females with preferential X-inactivation have more rapid
disease progression and suggested that X-inactivation is
the major factor for determining the severity of clinical
involvement and morbidity in Fabry heterozygotes.
However, for other authors [52], the phenotype was not
due to skewed X-inactivation, and severity was not corre-
lated with deviation either. They concluded that the X-
inactivation in leukocytes in females with Fabry disease is
not useful to predict prognostic and should not be used
to define therapeutic options. And disease progression
was related to a cross-correction mechanism which
would have a decreasing efficiency throughout the years,
which would explain the fact that heterozygote females
for Fabry disease get more symptomatic in time [22].
The cross-correction mechanism is also called meta-
bolic cooperation. Lysosomal enzymes freely enter and
leave lysosomes and are transferred from one cell to
another by manose-6-phosphate-mediated endocytosis.
When the enzyme is deficient, the non-digested pro-
ducts accumulate in the lysosome [87]. In Fabry disease,
either the amount of active enzyme secreted may be
insufficient, or the secreted enzyme is not adequately
taken up by normal cells, and this is not enough to
cross-correct the deficient synthesis of the abnormal
cells [16,21,87]. This last conclusion was suggested by
the fact that the activity of the enzyme in plasma or leu-
kocytes may not reflect the situation within the lyso-
some of relevant cell types of Fabry disease, which
suggests that the uptake by normal cells may be defec-
tive [12,16]. It seems that a distinct pattern of recapta-
tion due to the mannose-6-phosphate receptors and the
localization in the enzyme can be responsible for a
lower-uptake enzyme, and, as a consequence, some
females will manifest the disease [87]. In the case of
Pompe disease (a-glucosidase deficiency) a LD of auto-
somal recessive inheritance, abnormalities in the traf-
ficking of intracellular mannose-6-phosphate receptors
have been described. This would be the result of abnor-
mal substrate storage, with impact on the internalization
of the endogenous enzymes [94]. According to Dobyns
et al.[48] cross-correction ability in Fabry disease would
be largely restricted, as normal heterozygotes could pre-
sent skewed X-inactivation in favour of the normal
allele, and symptomatic heterozygotes may show ran-
dom X-inactivation (Table 3). Another hypothesis is
related to a new concept ("cross-induction”), for
increased levels of plasma lyso-Gb3 (a deacylated form
of Gb3) were found in symptomatic heterozygotes for
Fabry disease and appear to be positively correlated with
the severity of the clinical picture [95]. If this is true,
perhaps lyso-Gb3 is widely diffusible and has the capa-
city to inhibit a-GAL activity produced by cells which
have an active non-mutated X-chromosome leading,
therefore, to clinical symptomatology in most
heterozygotes.
The following other factors affect expression in Fabry
disease: 1) the nature of the mutation - and correlation
with enzyme activity [15], and 2) the blood group
(patients of blood groups B and AB are more severely
affected than individuals of other groups [8], probably
because these patients accumulate, in addition to globo-
triaosylceramie and galabiosylceramide, two further gly-
cosphingolipids [15]).
MPS II Disease: explanations for female phenotype
Different from Fabry carriers, heterozygote MPS II
females are spared from the disease. But why? It may be
attributed to the cross-correction of cells (in which the
active X is the one with the mutation) by the functional
enzyme secreted by cells in which the non-mutant gene
is active [96]. Schwartz et al.[ 9 7 ]s u g g e s t e dt h a ti n
some cells of MPS II carriers, like chondrocytes or hepa-
tocytes, the X chromosome carrying the mutant allele
would be preferentially inactivated or reduce cell viabi-
lity. Consequently, MPS II heterozygous females are
rarely affected unless there is a simultaneous presence
of two mutant alleles or if a coincidental genetic defect
happens, leading to skewed X-inactivation or hemizy-
gozity in heterozygotes (Table 3). According to Dobyns
et al. [48] as the cross-correction ability would be pre-
served in MPS II, the clinically normal heterozygotes
would present randomic X-inactivation or skewed X-
inactivation with predominant expression of the normal
X chromossome, while the symptomatic heterozygotes
would present skewed X-inactivation with predominant
expression of the mutated allele (Table 3). These find-
ings are in accordance with the literature, as shown in
Table S2, Additional file 2.
Concluding remarks and the future
Most females are mosaics and have a mixture of cells
expressing either their mother’so rf a t h e r ’sX - l i n k e d
genes. Often, cell mosaicismi sa d v a n t a g e o u s ,f o ri t
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and contributes to physiological diversity. Although
sometimes mosaicism brings a significant biological
advantage, the outcome is never certain [89].
It is interesting that, although Fabry disease and MPS
II are both X-linked LD, they show many differences in
clinical expression of heterozygous females. The main
differences, at the moment, could be explained by: 1)
cross-correction or cross-inducing mechanisms; 2) the
skewed X-inactivation [21].
As proposed by Dobyns et al. [48], the X-linked dis-
eases show a continuum in penetrance, and new rules
must be established to explain the various phenotypes
observed. Despite the fact that over 30 years have passed
since the discovery of the existence of the X-inactivation
mechanism, we still have a lot to learn, and new infor-
mation about cell biology is still needed to allow us to
p r o v i d eam o r ep r e c i s eg e n e t i cc o u n s e l i n gt oa f f e c t e d
families.
Consent
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